enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering...